Serum uric acid trajectories and risk of metabolic dysfunction-associated steatotic liver disease in China: a 2019-2021 cohort health survey

被引:0
作者
Shi, Dan [1 ]
Tan, Qilong [2 ,3 ]
Zhang, Yong [1 ,4 ]
Qi, Xiaoya [4 ]
Xu, Xiaoyang [4 ]
Xu, Guoqiong [4 ]
Bai, Ruixue [4 ]
Deng, Jing [4 ]
Chen, Mengxue [4 ]
Jiang, Tao [4 ]
Mei, Ying [4 ]
机构
[1] Chongqing Med Univ, Sch Publ Hlth, Chongqing 400016, Peoples R China
[2] Zhejiang Univ, Sch Publ Hlth, Sch Med, Hangzhou 310058, Zhejiang, Peoples R China
[3] Harbin Med Univ, Sch Publ Hlth, Harbin 150081, Heilongjiang, Peoples R China
[4] Chongqing Med Univ, Hosp 2, Dept Hlth Management, Chongqing 400011, Peoples R China
关键词
MASLD; Uric acid; Trajectory; China; FATTY LIVER; HEPATIC STEATOSIS; HYPERURICEMIA; HYPERTENSION; GENERATION; STRESS;
D O I
10.1186/s12889-024-21214-0
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
ObjectiveTo investigate the associations between serum uric acid (UA) trajectories and the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) in large cohort survey 2019-2021.MethodsThis cohort health survey included 11,644 participants without MASLD before January 1, 2021. Among them, 5578 (47.90%) were men and 6066 (52.10%) were women. The group-based trajectory model method was applied to identify serum UA trajectories from January 1, 2019, to December 30, 2021. New-onset MASLD events in 2021 were treated as outcomes. A logistic regression model was used to assess associations between UA trajectories and incidence of MASLD.ResultsFour distinct serum UA trajectories among both sexes were identified: "low-stable" trajectory 1 (n = 783 men; n = 1143 women), "moderate-moderate increasing" trajectory 2 (n = 2794 men; n = 3266 women), "moderate high-moderate increasing" trajectory 3 (n = 1660 men; n = 1464 women), and "high-increasing" trajectory 4 (n = 341 men; n = 193 women). During the 3-year follow-up period, 840 (15.06%) men and 408 (6.72%) women developed MASLD, respectively. Compared with the trajectory 1 group, the trajectory 4 group had the highest risk (odds ration [OR] 2.99 [95% confidence interval {CI} 1.70, 5.24] for men; OR 2.37 [95% CI 1.04, 5.33] for women), followed by the trajectory 3 (OR 2.23 [95% CI 1.52, 3.30] for men; OR 2.37 [95% CI 1.45, 3.92] for women) and trajectory 2 (OR 1.43 [95% CI 1.07, 1.94] for men; OR 1.37 [95% CI 0.93, 2.03] for women) groups.ConclusionsHigh serum UA trajectories were independent risk factors for MASLD in both sexes, which is critical for informing prevention and treatment strategies in public health initiatives and clinical practice.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Natural history of metabolic dysfunction-associated steatotic liver disease
    Lekakis, Vasileios
    Papatheodoridis, George, V
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 122 : 3 - 10
  • [32] Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Scarpellini, Emidio
    Scarcella, Marialaura
    Tack, Jan F.
    Scarlata, Giuseppe Guido Maria
    Zanetti, Michela
    Abenavoli, Ludovico
    ANTIOXIDANTS, 2024, 13 (11)
  • [33] Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study
    Simon, Tracey G.
    Ebrahimi, Fahim
    Roelstraete, Bjorn
    Hagstrom, Hannes
    Sundstrom, Johan
    Ludvigsson, Jonas F.
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [34] Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease
    Li, Yamei
    Qi, Ping
    Song, Si -Yuan
    Wang, Yiping
    Wang, Hailian
    Cao, Peng
    Liu, Yu 'e
    Wang, Yi
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 174
  • [35] Advances in research on metabolic dysfunction-associated steatotic liver disease
    Wang, Jiawang
    Wang, Zhongyu
    Yu, Yao
    Cheng, Si
    Wu, Jianping
    LIFE SCIENCES, 2025, 362
  • [36] Metabolic Dysfunction-Associated Steatotic Liver Disease: An Overview of Pharmacotherapy
    El Hussein, Mohamed
    Favell, Daniel
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2025, 21 (02):
  • [37] Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study
    Kim, Gi-Ae
    Jeong, Seogsong
    Jang, Heejoon
    Lee, Dong Hyeon
    Joo, Sae Kyung
    Kim, Won
    LIVER CANCER, 2024, 13 (04) : 426 - 437
  • [38] The Association of Serum Uric Acid with Risk of Obstructive Sleep Apnea: The Korean National Health and Nutrition Examination Survey 2019-2021
    Park, Su-Lim
    Lim, Jihye
    Lee, Ji-Ho
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (05):
  • [39] Association between metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction subtypes and risk of colorectal cancer: A prospective cohort study
    Li, Yuan
    Ma, Xiang-ming
    Jia, Jian-guo
    Cao, Li-ying
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2025, 49 (05)
  • [40] Progress in the Study of Animal Models of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Fu, Yu
    Hua, Yuxin
    Alam, Naqash
    Liu, Enqi
    NUTRIENTS, 2024, 16 (18)